Ranbaxy (India) in Brazil. Ranbaxy, an India-based pharmaceutical firm, has continuing problems with its cholesterol reduction product's price in one of its rapidly growing markets, Brazil. All product is produced in India, with costs and pricing initially stated in Indian rupees (Rps), but converted to Brazilian reais (R$) for distribution and sale in Brazil. In 2009, the unit volume was priced at Rps22,500, with a Brazilian real price set at R$895. But in 2010, the real appreciated in value versus the rupee, averaging Rps26.53/ R$. In order to preserve the real price and product profit margin in rupees, what should the new rupee price be set at? First, the implied spot exchange rate for the previous year, 2009 must be found. The implied spot exchange rate for the previous year, 2009 is Rps|/R$. (Round to two decimal places.) Assuming that Ranbaxy wishes to preserve the Brazilian real price for competitiveness, the same Brazilian real price must be converted back into Indian rupees with the new spot exchange rate in rupees per real. The new price is Rps (Round to two decimal places.) (Select from the drop-down menus.) Because the Indian rupee in value against the Brazilian real, the implied Indian rupee price is actually than it was the previous year. This means that Ranbaxy would keep the same price and either enjoy a much larger profit margin in price the same as the previous year and actually reduce the price. or potentially keep the